Australian Institute of Health Innovation, University of New South Wales, AGSM Building (Level 1), Paddington, NSW, 2052, Australia,
J Bioeth Inq. 2013 Oct;10(3):355-67. doi: 10.1007/s11673-013-9449-4. Epub 2013 Jun 7.
The pharmaceutical industry has been criticised for pervasive misconduct. These concerns have generally resulted in increasing regulation. While such regulation is no doubt necessary, it tends to assume that everyone working for pharmaceutical companies is equally motivated by commerce, without much understanding of the specific views and experiences of those who work in different parts of the industry. In order to gain a more nuanced picture of the work that goes on in the "medical affairs" departments of pharmaceutical companies, we conducted 15 semi-structured interviews with professionals working in medical departments of companies in Sydney, Australia. We show that this group of pharmaceutical professionals are committed to their responsibilities both to patients, research participants, and the public and to their companies. Despite the discrepancies between these commitments, our participants did not express much cognitive dissonance, and this appeared to stem from their use of two dialectically related strategies, one of which embraces commerce and the other of which resists the commercial imperative. We interpret these findings through the lens of institutional theory and consider their implications for pharmaceutical ethics and governance.
制药行业一直因其普遍存在的不当行为而受到批评。这些担忧通常导致了越来越多的监管。虽然这种监管无疑是必要的,但它往往假设在制药公司工作的每个人都同样受到商业利益的驱动,而对那些在行业不同部门工作的人的具体观点和经验缺乏了解。为了更细致地了解制药公司“医学事务”部门的工作情况,我们对澳大利亚悉尼的公司医学部门的 15 名专业人士进行了半结构化访谈。我们表明,这群制药专业人士对患者、研究参与者和公众以及他们的公司都有责任感。尽管这些承诺存在差异,但我们的参与者并没有表现出太多的认知失调,这似乎源于他们使用了两种辩证相关的策略,一种策略接受商业,另一种策略抵制商业冲动。我们通过制度理论的视角来解释这些发现,并考虑它们对制药伦理和治理的影响。